UBS Group AG - BRIACELL THERAPEUTICS CORP ownership

BRIACELL THERAPEUTICS CORP's ticker is BCTX and the CUSIP is 10778Y302. A total of 27 filers reported holding BRIACELL THERAPEUTICS CORP in Q3 2022. The put-call ratio across all filers is 0.08 and the average weighting 0.3%.

Quarter-by-quarter ownership
UBS Group AG ownership history of BRIACELL THERAPEUTICS CORP
ValueSharesWeighting
Q1 2023$1,259
-87.4%
169
-89.9%
0.00%
Q2 2022$10,000
+233.3%
1,672
+450.0%
0.00%
Q1 2022$3,000
-75.0%
304
-78.3%
0.00%
Q4 2021$12,000
-52.0%
1,402
-54.4%
0.00%
Q3 2021$25,000
-64.8%
3,077
-76.9%
0.00%
Q2 2021$71,000
+3450.0%
13,308
+2005.7%
0.00%
Q1 2021$2,0006320.00%
Other shareholders
BRIACELL THERAPEUTICS CORP shareholders Q3 2022
NameSharesValueWeighting ↓
Redmond Asset Management, LLC 131,731$508,0000.16%
SABBY MANAGEMENT, LLC 160,182$618,0000.12%
ZEKE CAPITAL ADVISORS, LLC 45,000$174,0000.01%
Freedom Investment Management, Inc. 16,339$63,0000.01%
Virtu Financial LLC 15,121$58,0000.00%
TORONTO DOMINION BANK 12$00.00%
ROYAL BANK OF CANADA 17$00.00%
UBS Group AG 632$2,0000.00%
OSAIC HOLDINGS, INC. 6,012$23,0000.00%
CONCOURSE FINANCIAL GROUP SECURITIES, INC. 0$00.00%
View complete list of BRIACELL THERAPEUTICS CORP shareholders